SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Amicus Therapeutics, Inc.

Levi & Korsinsky announces it has commenced an investigation of Amicus Therapeutics, Inc. ("Amicus Therapeutics" or the "Company") (NASDAQ: FOLD) concerning possible violations of federal securities laws by certain officers and directors.

On November 28, 2016, Amicus Therapeutics shares fell after hours following an announcement that the Food and Drug Administration will not grant an accelerated approval for its drug migalastat to treat Fabry disease. Shares of Amicus Therapeutics were down more than 21% on intraday trading on November 29, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/amicus-therapeutics-fold

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161129006127/en/
Copyright Business Wire 2010

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1